

---

## WilmerHale Advises Thermo Fisher Scientific in \$1.14B Sale of Anatomical Pathology Business

JANUARY 29, 2019

On January 28, 2019, Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it signed a definitive agreement to sell its Anatomical Pathology business to PHC Holdings Corporation, a global innovator in healthcare solutions, for approximately \$1.14 billion in cash. Thermo Fisher anticipates closing the transaction in the second quarter of 2019, subject to customary closing conditions and applicable regulatory approvals.

The WilmerHale team representing Thermo Fisher on the deal was led by [Hal Leibowitz](#), [Joe Conahan](#) and [Andrew Langworthy](#) and included [Robert Burke](#), [Ciara Baker](#), [John Sigel](#), [Justin Ochs](#), [Amy Null](#), [Scott Kilgore](#), [Ashwin Gokhale](#), [Christian Crones](#), [Lester Ross](#) and [Jasmine Haddad](#).

Read the [press release](#) announcing the signing of this agreement.